OLMA · XBRL financial data

Olema Pharmaceuticals financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OLMA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	51,100	82,274	86,140	124,517	157,697
General and administrative	20,391	24,714	18,821	17,741	21,001
Total operating expenses	71,491	106,988	104,961	142,258	178,698
Operating income (loss)	(71,491)	(106,988)	(104,961)	(142,258)	(178,698)
Interest income	442	2,228	8,325	12,682	16,224
Other income (expense)	(47)	(27)	(19)	102	23
Income tax expense (benefit)	—	1	2	2	3
Net income (loss)	(71,096)	(104,787)	(96,655)	(129,474)	(162,451)
Earnings per share, basic USD per share	(1.80)	(2.62)	(2.14)	(2.20)	(1.87)
Earnings per share, diluted USD per share	(1.80)	(2.62)	(2.14)	(2.20)	(1.87)
Weighted average shares, basic thousands of shares	39,524	39,995	45,247	58,744	87,006
Weighted average shares, diluted thousands of shares	39,524	39,995	45,247	58,744	87,006

Fiscal years (OLMA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	13,812	23,702	68,539	139,480	48,301
Marketable securities	273,438	180,719	193,268	294,606	457,136
Prepaid and other current assets	3,435	4,478	4,706	4,387	10,015
Total current assets	290,685	208,899	266,513	438,473	515,452
Property and equipment, net	1,474	1,480	968	746	274
Right-of-use asset	3,246	2,495	2,291	1,314	1,146
Total assets	295,945	215,645	276,945	450,979	533,430
Accounts payable	23	374	2,698	4,460	9,253
Total current liabilities	9,019	16,549	21,621	41,758	51,802
Lease liability, non-current	2,358	1,550	1,429	257	69
Total liabilities	11,377	18,099	23,050	42,015	54,871
Accumulated deficit	(104,190)	(208,977)	(305,632)	(435,106)	(597,557)
Total stockholders' equity	284,568	197,546	253,895	408,964	478,559
Total liabilities and equity	295,945	215,645	276,945	450,979	533,430
Common shares outstanding (cover page) thousands of shares	40,348	40,632	55,915	68,333	87,157

Fiscal years (OLMA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(71,096)	(104,787)	(96,655)	(129,474)	(162,451)
Stock-based compensation	15,913	18,829	17,256	22,582	17,586
Depreciation and amortization	163	357	377	393	490
Net cash from operating activities	(50,690)	(82,065)	(83,727)	(104,351)	(146,716)
Purchases of property and equipment	1,575	363	—	159	—
Net cash from investing activities	(275,438)	91,479	(4,851)	(93,526)	(155,760)
Net cash from financing activities	1,391	476	133,415	268,818	211,297
Net change in cash	(324,737)	9,890	44,837	70,941	(91,179)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Olema Pharmaceuticals	48,599	not reported	(45,896)*	87.5M	10.0 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199,270	not reported	(48,007)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	165,700	1,600	(51,500)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Heron Therapeutics	20,721	not reported	(2,213)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Corvus Pharmaceuticals	15,013	not reported	(12,215)*	84.4M	15.7 quarters	Q3 FY26 10-QSep 30, 2026
Verastem	172,801	24,012	(33,593)*	126.0M	4.0 quarters	Q3 FY26 10-QSep 30, 2026
Aldeyra Therapeutics	40,975	not reported	(4,124)*	60.4M	—	Q3 FY26 10-QSep 30, 2026
Sagimet Biosciences	165,896	not reported	(11,099)*	not reported	23.2 quarters	Q2 FY26 10-QJun 30, 2026
Atea Pharmaceuticals	76,548	not reported	(37,084)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 8, 2026, 5:31 AM ET. The filing on SEC.gov is the record.